언어 선택

Complement C1s

Complement C1s 분자 정보

영어 이름	Complement C1s	시판 약물 수	4
임상 약물 수	5	표적 별명	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
최고 연구 개발 단계	Approved

영어 이름	Complement C1s
표적 별명	EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
시판 약물 수	4
임상 약물 수	5
최고 연구 개발 단계	Approved

Complement C1s 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (1)Cynomolgus (1)
태그
His Tag (2)
마커
Unconjugated (2)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
COS-H52H3	Human	HEK293	Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)
COS-C52H3	Cynomolgus	HEK293	Cynomolgus Complement C1s Protein, His Tag (MALS verified)

총 수량2

Complement C1s분자 배경

Complement C1s is a serine protease and a key component of the C1 complex in the classical complement pathway. One C1q molecule binds to a tetramer composed of two C1r and two C1s proteases to form the intact C1 complex. C1s circulates as a zymogen until activated by proteolytic cleavage from activated C1r. Its essential function is to cleave complement components C4 and C2, thereby initiating the formation of the C3 convertase (C4b2a). This step is critical for triggering downstream immune effector functions, including opsonization, inflammation, and membrane attack complex formation.

Complement C1s분자 별명

EDSPD2

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Complement-C1 inhibitor protein (Octapharma)		Phase 3 Clinical	Octapharma	Angioedemas, Hereditary	상세
Riliprubart	BIVV-020; SAR-445088; TNT-020	Phase 3 Clinical	True North Therapeutics	Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic	상세
C1 esterase inhibitor (Boya Bio-Pharmaceutical)		Phase 3 Clinical	Boya Bio-Pharmaceutical Group Co Ltd	Angioedemas, Hereditary	상세
Claseprubart	DNTH103; DNTH-103	Phase 3 Clinical	Dianthus Therapeutics Inc	Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating	상세
C1 esterase inhibitor (Chengdu Institute of Biological Products)		Phase 1 Clinical	Chengdu Institute Of Biological Products Co Ltd	Angioedemas, Hereditary	상세

시판 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	가장 빠른 브랜드 이름	가장 빠른 승인 국가	가장 빠른 적응증	가장 빠른 승인 회사	가장 빠른 승인 날짜	적응증	임상 시험
Conestat alfa	rhC1-INH	Approved	Pharming Group Nv	Rhucin, Esterasine, Ruconest	EU	Angioedemas, Hereditary	Pharming Group Nv	2010-10-28	Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency	상세
Sutimlimab	BIVV-009; TNT-009	Approved	True North Therapeutics	ENJAYMO	United States	Anemia, Hemolytic, Autoimmune	Recordati Rare Diseases Inc	2022-02-04	Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic	상세
Complement C1 inhibitor protein (Shire ViroPharma)	C1 INH-nf; C1-INH; SHP-616	Approved	Sanquin Plasma Products Bv	Cinryze, Cetor	United States	Angioedemas, Hereditary	null	2008-10-10	Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation	상세
C1 esterase inhibitor (Human, CSL Behring)	BI-3.012; CSL-830; CSL-842; CE-1145	Approved	Csl Behring Llc	Berinert, Haegarda, Berinert 2000	Japan	Angioedemas, Hereditary	Csl Behring Llc	1990-06-29	Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation	상세